BiotechTube
Home/ImmunoScape/Michael Fehlings, PhD
MF

Michael Fehlings, PhD

Chief Executive Officer

ImmunoScape

Therapeutic Areas

Oncology

ImmunoScape Pipeline

DrugIndicationPhase
IS-001WT1‑positive solid tumorsPhase 1
CUE-102WT1‑positive tumors (booster)Phase 1

Leadership Team at ImmunoScape

RC
Romi Chandiramani, CA
Chief Financial Officer
AN
Alessandra Nardin, DVM
Vice President, Strategy
TK
Tan Kar Wai, PhD
Vice President, Discovery and Preclinical Sciences
AB
Andrian Bot, MD/PhD
Chief Scientific Officer
View full ImmunoScape profile